Wide Ranks

CYCCP

Cyclacel Pharmaceuticals, Inc.

6.75

Top Statistics
Market Cap 12 M Forward PE 0.0000 Revenue Growth -98.90 %
Current Ratio 1.07 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 9.84 %
Enterprice / EBITA -0.3000 Enterprise / Revenue 75.60 Price To Sales Trailing12 Months 160.44
Profitability
Profit Margins 0.00 % Operating Margins -91100.00 %
Balance Sheet
Total Cash 6 M Total Cash Per Share 3.04 Total Debt 5000
Total Debt To Equity 0.5010 Current Ratio 1.07 Book Value Per Share 0.5730
All Measures
Message Board Id finmb_125004 Fax 866 271 3466 Return On Equity -5.71
City Berkeley Heights Uuid 30e2be38-8d7d-375a-841a-72cfbb0be0a4 Previous Close 6.49
First Trade Date Epoch Utc 1 B Book Value 0.5730 Beta 0.5570
Total Debt 5000 Volume 396 Price To Book 11.78
Fifty Two Week Low 5.55 Total Cash Per Share 3.04 Total Revenue 80000
Shares Short Previous Month Date 1 B Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -91100.00 % Last Dividend Value 0.1500 Net Income To Common -17606000
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 260
Average Volume10days 260 Total Cash 6 M Next Fiscal Year End 1 B
Revenue Per Share 0.0440 Held Percent Insiders 0.0048 Dividend Rate 0.6000
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 6.49 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 6.99 Open 6.70 Dividend Yield 9.84 %
State NJ Free Cashflow -7656750 Return On Assets -1.03
Time Zone Short Name EST Trailing Eps -2.05 Day Low 6.70
Address1 200 Connell Drive Shares Outstanding 12 M Price Hint 2
Target High Price 0.0000 Website https://www.cyclacel.com 52 Week Change -0.2582
Average Volume 357 Recommendation Key none Forward Eps 0.0000
Compensation As Of Epoch Date 1 B Quick Ratio 97.00 % Is_sp_500 False
Regular Market Day High 6.75 Profit Margins 0.00 % Debt To Equity 0.5010
Fifty Two Week High 22.20 Day High 6.75 Regular Market Open 6.70
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 75.60
Revenue Growth -98.90 % Operating Cashflow -11513000 Five Year Avg Dividend Yield 730.00 %
Currency USD Market Cap 12 M Time Zone Full Name America/New_York
Is_nasdaq_100 False Zip 07922 Quote Type EQUITY
Industry Biotechnology Ex Dividend Date 1 B Regular Market Day Low 6.70
Held Percent Institutions 0.0003 Long Name Cyclacel Pharmaceuticals, Inc. Current Price 6.75
Address2 Suite 1500 Enterprise To Ebitda -0.3000 Financial Currency USD
Current Ratio 1.07 Gross Margins 100.00 % Industry Disp Biotechnology
Country United States Float Shares 1 M Two Hundred Day Average 10.35
Enterprise Value 6 M Price To Sales Trailing12 Months 160.44 Forward PE 0.0000
Regular Market Volume 396 Last Dividend Date 1 B Ebitda -20185000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally.

The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.

It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.

The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.